Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 165

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial

Open access
Dunning, Jake, Sahr, Foday, Rojek, Amanda, Gannon, Fiona, Carson, Gail, Idriss, Baimba, Massaquoi, Thomas, Gandi, Regina, Joseph, Sebatu, Osman, Hassan K., Brooks, Timothy J. G., Simpson, Andrew J. H., Goodfellow, Ian, Thorne, Lucy, Arias, Armando, Merson, Laura, Castle, Lyndsey, Howell-Jones, Rebecca, Pardinaz-Solis, Raul, Hope-Gill, Benjamin, Ferri, Mauricio, Grove, Jennifer, Kowalski, Mark, Stepniewska, Kasia, Lang, Trudie, Whitehead, John, Olliaro, Piero, Samai, Mohammed, Horby, Peter W., for the RAPIDE-TKM trial team·2016·PLOS Medicine

Abstract

BACKGROUND: TKM-130803, a small interfering RNA lipid nanoparticle product, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety in humans has not been evaluated. METHODS AND FINDINGS: In this single-arm phase 2 trial, adults with laboratory-confirmed EVD received 0.3 mg/kg of TKM-130803 by intravenous infusion once daily for up to 7 d. On days when trial enrolment capacity was reached, patients were enrolled into a concurrent observational cohort. The primary outcome was survival to day 14 after admission, excluding patients who died within 48 h of admission. After 14 adults with EVD had received TKM-130803, the pre-specified futility boundary was reached, indicating a probability of survival to day 14 of ≤0.55, and enrolment was stopped. Pre-treatment geometric mean Ebola virus load in the 14 TKM-130803 recipients was 2.24 × 109 RNA copies/ml plasma (95% CI 7.52 × 108, 6.66 × 109). Two of the TKM-130803 recipients died within 48 h of admission and were therefore excluded from the primary outcome analysis. Of the remaining 12 TKM-130803 recipients, nine died and three survived. The probability that a TKM-130803 recipient who survived for 48 h will subsequently survive to day 14 was estimated to be 0.27 (95% CI 0.06, 0.58). TKM-130803 infusions were well tolerated, with 56 doses administered and only one possible infusion-related reaction observed. Three patients were enrolled in the observational cohort, of whom two died. CONCLUSIONS: Administration of TKM-130803 at a dose of 0.3 mg/kg/d by intravenous infusion to adult patients with severe EVD was not shown to improve survival when compared to historic controls. TRIAL REGISTRATION: Pan African Clinical Trials Registry PACTR201501000997429.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1371/journal.pmed.1001997

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 165

Metadata

Authors
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., Brooks, T. J. G., Simpson, A. J. H., Goodfellow, I., Thorne, L., Arias, A., Merson, L., Castle, L., Howell-Jones, R., Pardinaz-Solis, R., Hope-Gill, B., Ferri, M., Grove, J., Kowalski, M., Stepniewska, K., Lang, T., Whitehead, J., Olliaro, P., Samai, M., Horby, P. W., & for the RAPIDE-TKM trial team
Venue
PLOS Medicine
Published
2016-04-19
Volume
13
Issue
4
Pages
e1001997
ISSN
  • 1549-1277 (ISSN-L)
  • 1549-1676
OpenAlex
W2336471513
Cited by
165
References
2
FWCI
26.60
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. https://app.cochat.ai/papers/10.1371/journal.pmed.1001997
The paper
Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., Brooks, T. J. G., Simpson, A. J. H., Goodfellow, I., Thorne, L., Arias, A., Merson, L., Castle, L., Howell-Jones, R., Pardinaz-Solis, R., . . . for the RAPIDE-TKM trial team. (2016). Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. PLOS Medicine. https://doi.org/10.1371/journal.pmed.1001997

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.